Dalpiciclib Isethionate

羟乙磺酸达尔西利

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameDalpiciclib Isethionate
Drug Alias Name达尔西利DalcilibDalpicicilipDalpciclib艾瑞康 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 6Cyclin-dependent kinase 4
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursHepatic Insufficiency +[11] 
Global Approved IndicationsMetastatic breast cancerBreast Neoplasms
Approved Indications in ChinaMetastatic breast cancerBreast Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2021/12/31
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesFudan UniversityShanghai Hengrui Pharmaceutical Co LtdJiangsu Hengrui Medicine Co Ltd
Inactive CompaniesPeking UniversitySun Yat-Sen UniversityAtridia Pty Ltd
Active IndicationsMetastatic breast cancerSolid tumoursHepatic Insufficiency +[6] 
Inactive IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungStomach Neoplasms +[5] 

Other Information

ATC CodeL01EF
Related LinksDrugBank